Early life surfactant protein-D levels in bronchoalveolar lavage fluids of extremely preterm neonates
Loading...
Official URL
Full text at PDC
Publication date
2023
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
American Physiological Society
Citation
Early life surfactant protein-D levels in bronchoalveolar lavage fluids of extremely preterm neonates Daniele De Luca, Raquel Arroyo, Silvia Foligno, Chiara Autilio, Lhousseine Touqui, and Paul S. Kingma American Journal of Physiology-Lung Cellular and Molecular Physiology 2023 325:4, L411-L418
Abstract
Surfactant protein-D (SP-D) is a hydrophilic protein with multiple crucial anti-inflammatory and immunological functions. It might play a role in the development and course of pulmonary infections, acute respiratory distress syndrome, and other respiratory disorders. Only few small neonatal studies have investigated SP-D: we aimed to investigate the links between this protein, measured in the first hours of life in extremely preterm neonates, and clinical outcomes, as well its relationship with pulmonary secretory phospholipase A2 (sPLA2). Bronchoalveolar lavage fluids were obtained within the first 3 h of life. SP-D and sPLA2 were measured with ELISA and radioactive method, respectively; epithelial lining fluid concentrations were estimated with urea ratio. Clinical data were prospectively collected. One hundred extremely preterm neonates were nonconsecutively studied. SP-D was significantly raised with increasing gestational age (24–26 wk: 68 [0–1,694], 27 or 28 wk: 286 [0–1,328], 29 or 30 wk: 1,401 [405–2,429] ng/mL, overall P = 0.03). SP-D was significantly higher in cases with clinical chorioamnionitis with fetal involvement (1,138 [68–3,336]) than in those without clinical chorioamnionitis with fetal involvement (0 [0–900] ng/mL, P < 0.001). SP-D was lower in infants with bronchopulmonary dysplasia (BPD) (251 [0–1,550 ng/mL]) compared with those without bronchopulmonary dysplasia (BPD) or who died before its diagnosis (977 [124–5,534 ng/mL], P = 0.05) and this was also significant upon multivariate analysis [odds ration (OR): 0.997 (0.994–0.999), P = 0.024], particularly in neonates between 27- and 28-wk gestation. SP-D significantly correlated with the duration of hospital stay (ρ = −0.283, P = 0.002), invasive ventilation (ρ = −0.544, P = 0.001), and total sPLA2 activity (ρ = 0.528, P = 0.008). These findings help understanding the role of SP-D early in life and support further investigation about the role of SP-D in developing BPD.
Description
D. De Luca has received research and educational grants from Chiesi Pharmaceuticals and ABBVIE. He served as consultant and lecturer for Airway Therapeutics, Chiesi Pharmaceuticals, and ABBVIE. Finally, he has been or is a member of advisory boards for Chiesi Pharmaceuticals, Ophirex, and ABBVIE: these companies produce surfactants or surfactant-related molecules. L. Touqui has received research grants and assistance from Chiesi Pharmaceuticals, which produces surfactant. P. S. Kingma served as Chief Medical Officer from 2018 to 2021 for Airway Therapeutics, which is developing SPD as a human therapeutic agent; however, P. S. Kingma terminated all financial relationships with Airway Therapeutics in 2021. R. Arroyo is currently an employee of Airway Therapeutics Inc. The declared conflicts are all unrelated to the present work. None of the other authors has any conflicts of interest, financial or otherwise, to disclose.